来自MSN2 个月
Applied Therapeutics' Govorestat Faces 'Significant' Uncertainty in Galactosemia Treatment ...Galactosemia is a rare genetic metabolic disease that leads to an inability to metabolize the simple sugar galactose. The company's shares plunged 75% in Friday afternoon trade. The stock has lost ...
Galactosemia (G) is due to either partial or complete deficiency of the enzyme galactose-1-phosphate uridyl transferase (Ts). In females with G, there is a high incidence of premature ovarian failure.
The NDA for govorestat for the galactosemia indication was accepted by the FDA in late February under its Priority Review pathway. Year to date, shares of Applied Therapeutics have skyrocketed 155 ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果